MedTrace Logo

Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic Cough

NCT03282591 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 185

Last updated 2021-05-20

Study results available
· View outcomes & findings →

Summary

Study of the efficacy, safety, and tolerability of serlopitant for the treatment of refractory chronic cough

Conditions

  • Refractory Chronic Cough

Interventions

DRUG

5 mg Serlopitant Tablets

Serlopitant Tablets

DRUG

Matching Placebo Tablets

Placebo Tablets

Sponsors & Collaborators

  • Vyne Therapeutics Inc.

    lead INDUSTRY

Principal Investigators

  • Jacky Smith · University of Manchester, United Kingdom

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-03
Primary Completion
2018-08-15
Completion
2018-09-06
FDA Drug
Yes

Countries

  • United States
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03282591 on ClinicalTrials.gov